CD68 and rectal cancer: Nevertheless, a study by Kitagawa et al. on pre-treatment biopsies from 275 patients with rectal cancer treated with neoadjuvant CRT showed that low CD68+ macrophage counts were more frequently recorded in tumors that poorly responded to CRT [87].